LIVER
The absolute number of Chronic Liver Disease cases is estimated at 1.5 billion worldwide. According to the FDA, Drug-Induced Liver Injury has been the most frequent single cause of safety-related drug marketing withdrawals for the past 50 years and is often associated with acute liver failures.
Platform Features
World’s first commercial biobank for renewable liver cells from induced pluripotent stem cells.
Multicellular modelling with three major types of liver cells (stellates, Kupffer cells, and endothelial cells) to mimic liver microarchitecture.
Robust data platform powered by transcriptomics and genotyping for biomarker discovery.
“On a chip” technology for microphysiological modelling. Patient-derived samples for studying genetic predisposition and treatment response variability.
Hepatitis C
Stemnovate is working with Prof Cliona O’Farrelly at Trinity College, Ireland, to find out why some people can block infection by hepatitis C in a bid to improve treatment.
Nash
Non-alcoholic steatohepatitis (NASH) is a form of fatty liver disease (steatosis) that, untreated, can progress to fibrosis, cirrhosis and hepatocellular cancer.
We help reduce diagnostic invasive liver biopsies and improve treatment response by providing technology for early detection and severity assessment.
There is an urgent need for technology for early detection and assessment of the severity of Liver diseases . Stemnovate brings to market liver platform that can help the scientific community, clinicians and pharma develop better diagnosis and novel treatments
Grants for research and innovation
Stemnovate won an NC3R Grant to develop a liver model alternative to animal testing for yellow fever vaccine development. The challenge was sponsored by the pharmaceutical company Sanofi.